Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 307

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 307
---
 from $7.01 per share to $0.01 per share and the addition of performance and vesting conditions, not currently considered probable of achievement, related to corporate transactions. In the year ended May 31, 2024, stock -basedcompensation expense amounted to $194,846, of which $182,912 is included in research and development expenses and $11,934 is included in general and administrative expenses. In the year ended May 31, 2023, stock -basedcompensation expense amounted to $966,214, of which $435,187 is included in research and development expenses and $531,027 is included in general and administrative expenses. As of May 31, 2024, unrecognized stock -basedcompensation expense related to options for which vesting is considered probable was $24,310, which is expected to be recognized over a remaining weighted -averageperformance period of 0.3 years. As of May 31, 2024, unrecognized stock -basedcompensation expense related to options for which vesting is not considered probable was $1,093,712. In the year ended May 31, 2023, DiamiR issued 132,000 restricted stock units, vesting upon a change in control or public listing of DiamiR’s common stock. In the year ended May 31, 2024, concurrent with the modification of stock options described above, DiamiR terminated outstanding restricted stock units representing 44,000shares. Vesting of the units is not considered probable and no compensation expense has been recognized through the year ended May 31, 2024. The grant -datefair value and unrecognized compensation expense as of May 31, 2023 related to the restricted stock units amounts to $652,080. There was no additional stock option activity in the nine months ended February 28, 2025. Laboratory Acquisition and Intangible Assets On April 15, 2021, pursuant to an Asset Purchase Agreement, DiamiR acquired certain laboratory assets, facilities and operations from Interpace, a provider of molecular diagnostic tests. The total purchase consideration consisted of 42,820shares DiamiR common stock with an estimated fair value of $300,000.

179

At acquisition, the laboratory was in active operation, providing services to third -parties, and DiamiR accounted for the acquisition as the purchase of a business in accordance with FASB ASC Topic 805 Business Combinations. Accordingly, DiamiR recorded